Similar articles

• Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

  O'Sullivan H, Collins D, O'Reilly S. O'Sullivan H, et al. N Engl J Med. 2019 Mar 7;380(10):986. doi: 10.1056/NEJMc1900150. N Engl J Med. 2019. PMID: 30855755 No abstract available.
• Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.

  Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators. Schmid P, et al. Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27. Lancet Oncol. 2020. PMID: 31786121 Clinical Trial.
• Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

  Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators. Schmid P, et al. N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20. N Engl J Med. 2018. PMID: 30345906 Clinical Trial.
• Atezolizumab (in Combination with Nab-Paclitaxel): A Review in Advanced Triple-Negative Breast Cancer.

  Kang C, Syed YY. Kang C, et al. Drugs. 2020 Apr;80(6):601-607. doi: 10.1007/s40265-020-01295-y. Drugs. 2020. PMID: 32248356 Review.
• Atezolizumab in the treatment of metastatic triple-negative breast cancer.

  Pérez-García J, Soberino J, Racca F, Gion M, Stradella A, Cortés J. Pérez-García J, et al. Expert Opin Biol Ther. 2020 Sep;20(9):981-989. doi: 10.1080/14712598.2020.1769063. Epub 2020 May 25. Expert Opin Biol Ther. 2020. PMID: 32450725 Review.